• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The impact of the COVID-19 pandemic on patients with systemic vasculitis: a single-centre retrospective study.COVID-19 大流行对系统性血管炎患者的影响:一项单中心回顾性研究。
Rheumatol Int. 2023 Mar;43(3):459-466. doi: 10.1007/s00296-023-05276-8. Epub 2023 Jan 16.
2
Clinical and anamnestic features of patients with systemic vasculitis: a single-center retrospective study.系统性血管炎患者的临床和病史特征:一项单中心回顾性研究。
Rheumatol Int. 2024 Apr;44(4):687-692. doi: 10.1007/s00296-024-05533-4. Epub 2024 Feb 6.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
5
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.未确诊的强直性脊柱炎病例中的血清阳性视神经脊髓炎:一个神经风湿病学难题
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.
6
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.伊维菌素预防 COVID-19 患者住院(IVERCOR-COVID19):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.
7
Single-organ gallbladder vasculitis: characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 61 patients.单器官胆囊血管炎:特征及与累及胆囊的系统性血管炎的鉴别。61例患者分析
Medicine (Baltimore). 2014 Nov;93(24):405-413. doi: 10.1097/MD.0000000000000205.
8
A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic.一项关于大流行初期系统性血管炎和 COVID-19 的单中心调查研究。
Turk J Med Sci. 2021 Oct 21;51(5):2243-2247. doi: 10.3906/sag-2010-267.
9
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
10
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study.来自COVID-19全球风湿病联盟医生登记处的原发性系统性血管炎或风湿性多肌痛患者的COVID-19结局:一项回顾性队列研究。
Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi: 10.1016/S2665-9913(21)00316-7. Epub 2021 Nov 5.

引用本文的文献

1
SARS-CoV-2 as a trigger of IgA vasculitis: a clinical case and literature review.SARS-CoV-2 作为 IgA 血管炎的触发因素:临床病例及文献复习。
Rheumatol Int. 2024 Nov;44(11):2613-2620. doi: 10.1007/s00296-024-05712-3. Epub 2024 Sep 9.

本文引用的文献

1
Physicians' perceptions about antineutrophil cytoplasmic antibody-associated vasculitis: an online survey report in the time of the COVID-19 pandemic.医生对中性粒细胞胞浆抗体相关性血管炎的认知:COVID-19 大流行时期的在线调查报告。
Clin Rheumatol. 2023 Mar;42(3):831-837. doi: 10.1007/s10067-022-06452-0. Epub 2022 Nov 21.
2
Large-vessel vasculitis.大血管血管炎
Nat Rev Dis Primers. 2022 Jan 6;7(1):93. doi: 10.1038/s41572-021-00327-5.
3
Takayasu arteritis - epidemiology, pathogenesis, diagnosis and treatment.高安动脉炎——流行病学、发病机制、诊断与治疗
J Appl Biomed. 2019 Mar;17(1):20. doi: 10.32725/jab.2018.005. Epub 2019 Jan 9.
4
ANCA-Associated Vasculitis: An Update.抗中性粒细胞胞浆抗体相关血管炎:最新进展
J Clin Med. 2021 Apr 1;10(7):1446. doi: 10.3390/jcm10071446.
5
Effects of the COVID-19 Pandemic on Patients Living With Vasculitis.新冠疫情对血管炎患者的影响。
ACR Open Rheumatol. 2021 Jan;3(1):17-24. doi: 10.1002/acr2.11204. Epub 2020 Dec 8.
6
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation.2019 年冠状病毒病(COVID-19)合并系统性自身免疫性疾病或血管炎患者的影像学表现。
J Thromb Thrombolysis. 2021 Feb;51(2):339-348. doi: 10.1007/s11239-020-02289-z. Epub 2020 Sep 26.
7
COVID-19-associated vasculitis and vasculopathy.COVID-19 相关血管炎和血管病变。
J Thromb Thrombolysis. 2020 Oct;50(3):499-511. doi: 10.1007/s11239-020-02230-4.
8
Pathophysiology and therapy of systemic vasculitides.系统性血管炎的病理生理学与治疗
EXCLI J. 2020 Jun 18;19:817-854. doi: 10.17179/excli2020-1512. eCollection 2020.
9
SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.SARS-CoV-2 内皮感染导致 COVID-19 冻疮样皮疹:7 例儿科病例的组织病理学、免疫组织化学和超微结构研究。
Br J Dermatol. 2020 Oct;183(4):729-737. doi: 10.1111/bjd.19327. Epub 2020 Aug 5.
10
Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.系统性血管炎的流行病学、危险因素和结局的最新进展。
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):271-294. doi: 10.1016/j.berh.2018.09.001. Epub 2018 Nov 2.

COVID-19 大流行对系统性血管炎患者的影响:一项单中心回顾性研究。

The impact of the COVID-19 pandemic on patients with systemic vasculitis: a single-centre retrospective study.

机构信息

Department of Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.

Department of Clinical Rheumatology and Immunology, University Hospital in Krakow, Krakow, Poland.

出版信息

Rheumatol Int. 2023 Mar;43(3):459-466. doi: 10.1007/s00296-023-05276-8. Epub 2023 Jan 16.

DOI:10.1007/s00296-023-05276-8
PMID:36645477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9842200/
Abstract

This study aimed to study the impact of the COVID-19 pandemic on patients living with systemic vasculitis in Kazakhstan. A single-centre retrospective study of the medical histories of 82 patients was carried out based on the regional clinical hospital of the city for all admissions with systemic vasculitis in the period from January 2019 to December 2021. The following qualitative (gender, disability, concomitant diseases) and quantitative (age, disease experience, laboratory data, etc.) variables were studied. To conduct the study, the criteria for the inclusion and exclusion of patients in the study were determined. According to the results of the study, there is a decrease in the number of hospitalized patients with vasculitis in the rheumatology department of the regional clinical hospital. Compared to 2019, in 2021, the number of hospitalized patients decreased by almost half (Table 1). Out of 82 cases, the most common was Takayasu disease (nonspecific aortoarteritis) (43.9%), IgA-vasculitis (Schenlein-Genoch disease) (31.71%), and they are typical mainly for females of rural origin, who were admitted to the hospital in a comorbid state (p < 0.001). 41.6% of patients have disabilities, and the majority of patients have a II disability group. The average body mass index is 24.2; 27 patients out of the total number of patients suffer from obesity. The most common clinical symptoms of patients with systemic vasculitis were injuries of the musculoskeletal system (75.6%). A negative average correlation was found between the indicators of the level of ESR and haemoglobin, the correlation coefficient is -0.535. The patients had concomitant diseases, such as diabetes mellitus, iron deficiency anaemia, coronary heart disease, hypertension, gastrointestinal tract diseases and hepatitis. Women of reproductive age from rural areas are often diagnosed with systemic vasculitis. A high rate of disability revealed among the patients can be explained by two main factors, the first is that the patients consulted the doctors untimely and the second is that the medical community are insufficiently informed about the management of autoimmune rheumatic diseases, in particular about systemic vasculitis, which hinders timely diagnosis and treatment, respectively. Patients, included in this survey, were mostly suffering from diseases of the musculoskeletal system, but depending on the type of vasculitis, other organs and systems may be affected. Table 1 Frequency of patients with systemic vasculitis over 3 years Year Frequency % p-value 2019 42 51.2 χ = 12.463; p = 0.002 2020 23 28.0 2021 17 20.7 Total 82 100.0.

摘要

这项研究旨在研究 COVID-19 大流行对哈萨克斯坦系统性血管炎患者的影响。基于该市区域临床医院,对 2019 年 1 月至 2021 年 12 月期间所有因系统性血管炎入院的患者进行了 82 例患者的单中心回顾性研究。研究了以下定性(性别、残疾、并存疾病)和定量(年龄、疾病经历、实验室数据等)变量。为了进行研究,确定了患者纳入和排除研究的标准。根据研究结果,区域临床医院风湿科住院血管炎患者数量有所减少。与 2019 年相比,2021 年住院患者数量减少了近一半(表 1)。在 82 例病例中,最常见的是 Takayasu 病(非特异性主动脉炎)(43.9%)、IgA-血管炎(Schenlein-Genoch 病)(31.71%),它们主要发生在农村地区的女性,她们以合并症的状态入院(p<0.001)。41.6%的患者有残疾,大多数患者属于 II 组残疾。平均体重指数为 24.2;27 名患者患有肥胖症。系统性血管炎患者最常见的临床症状是肌肉骨骼系统损伤(75.6%)。发现 ESR 和血红蛋白水平之间存在负平均相关性,相关系数为-0.535。患者存在糖尿病、缺铁性贫血、冠心病、高血压、胃肠道疾病和肝炎等并存疾病。农村地区的育龄妇女经常被诊断为系统性血管炎。患者中发现高残疾率的原因可能有两个,第一个是患者没有及时就医,第二个是医疗界对自身免疫性风湿病的管理,尤其是对系统性血管炎的管理了解不足,分别导致了延误诊断和治疗。参与这项调查的患者主要患有肌肉骨骼系统疾病,但根据血管炎的类型,其他器官和系统也可能受到影响。表 1 3 年内系统性血管炎患者的频率 年份 频率 % p 值 2019 42 51.2 χ=12.463;p=0.002 2020 23 28.0 2021 17 20.7 总计 82 100.0.